Kadimastem Financials

KDST Stock  ILA 51.30  3.40  6.22%   
Financial data analysis helps to check out if markets are presently mispricing Kadimastem. We were able to interpolate twenty-nine available fundamentals for Kadimastem, which can be compared to its peers in the industry. To ensure the equity is not overpriced, please verify all Kadimastem financials, including its shares outstanding, shares owned by institutions, price to book, as well as the relationship between the shares owned by insiders and price to earning . The stock experiences a very speculative upward sentiment. Check odds of Kadimastem to be traded at 48.73 in 90 days.
With this module, you can analyze Kadimastem financials for your investing period. You should be able to track the changes in Kadimastem individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past Kadimastem Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Kadimastem's financial statements are interrelated, with each one affecting the others. For example, an increase in Kadimastem's assets may result in an increase in income on the income statement.
Evaluating Kadimastem's financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Kadimastem's profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Kadimastem's relative financial performance

Chance Of Distress

Less than 42

 
100  
 
Zero
Below Average
Kadimastem has less than 42 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Kadimastem stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Kadimastem's odds of distress score SHOULD NOT be confused with the real chance of Kadimastem filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Kadimastem is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Kadimastem's liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in Kadimastem's official financial statements usually reflect Kadimastem's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kadimastem. For example, before you start analyzing numbers published by Kadimastem accountants, it's critical to develop an understanding of what Kadimastem's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Kadimastem's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kadimastem's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kadimastem's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kadimastem. Please utilize our Beneish M Score to check the likelihood of Kadimastem's management manipulating its earnings.

Kadimastem Company Summary

Kadimastem competes with Bank Leumi, Mizrahi Tefahot, Gazit Globe, Alony Hetz, and Delek. Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. The company was founded in 2008 and is based in Ness Ziona, Israel. KADIMASTEM operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 28 people.
InstrumentIsrael Stock View All
ExchangeTel Aviv Stock Exchange
ISINIL0011284614
Business AddressPinchas Sapir 7,
SectorBiotechnology
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.kadimastem.com
Phone972 73 797 1600
CurrencyILA
You should never invest in Kadimastem without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Kadimastem Stock, because this is throwing your money away. Analyzing the key information contained in Kadimastem's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Kadimastem Key Financial Ratios

Generally speaking, Kadimastem's financial ratios allow both analysts and investors to convert raw data from Kadimastem's financial statements into concise, actionable information that can be used to evaluate the performance of Kadimastem over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Kadimastem reports annually and quarterly.

Kadimastem Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Kadimastem's current stock value. Our valuation model uses many indicators to compare Kadimastem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kadimastem competition to find correlations between indicators driving Kadimastem's intrinsic value. More Info.
Kadimastem is currently regarded as number one stock in current liabilities category among related companies. It is currently regarded as number one stock in cash and equivalents category among related companies creating about  0.49  of Cash And Equivalents per Current Liabilities. The ratio of Current Liabilities to Cash And Equivalents for Kadimastem is roughly  2.03 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Kadimastem by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kadimastem's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kadimastem's earnings, one of the primary drivers of an investment's value.

Kadimastem Systematic Risk

Kadimastem's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kadimastem volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Kadimastem correlated with the market. If Beta is less than 0 Kadimastem generally moves in the opposite direction as compared to the market. If Kadimastem Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kadimastem is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kadimastem is generally in the same direction as the market. If Beta > 1 Kadimastem moves generally in the same direction as, but more than the movement of the benchmark.

About Kadimastem Financials

What exactly are Kadimastem Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Kadimastem's income statement, its balance sheet, and the statement of cash flows. Potential Kadimastem investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Kadimastem investors may use each financial statement separately, they are all related. The changes in Kadimastem's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kadimastem's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze Kadimastem Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Kadimastem is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Kadimastem has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Kadimastem's financials are consistent with your investment objective using the following steps:
  • Review Kadimastem's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Kadimastem's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Kadimastem's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Kadimastem's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

Kadimastem March 29, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Kadimastem help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kadimastem. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kadimastem based on widely used predictive technical indicators. In general, we focus on analyzing Kadimastem Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kadimastem's daily price indicators and compare them against related drivers.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kadimastem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Kadimastem Stock analysis

When running Kadimastem's price analysis, check to measure Kadimastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kadimastem is operating at the current time. Most of Kadimastem's value examination focuses on studying past and present price action to predict the probability of Kadimastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kadimastem's price. Additionally, you may evaluate how the addition of Kadimastem to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Fundamental Analysis
View fundamental data based on most recent published financial statements
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Please note, there is a significant difference between Kadimastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kadimastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kadimastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.